Developer docs
API playgroundTry for free, no card

Search company profiles

Tango Therapeutics

Full company profile

uuid000053q

Namestring
Tango Therapeutics
Legal namestring
Tango Therapeutics, Inc.
Websiteurl
tangotx.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Tango Therapeutics is a clinical-stage biotechnology company developing next-generation precision oncology medicines based on the principle of synthetic lethality. Founded in 2017 and headquartered in Boston, Massachusetts, the company is publicly listed on NASDAQ under ticker TNGX and employs between 101 and 250 people. Tango's core technology is a proprietary CRISPR-based functional genomics target discovery platform that integrates targets, pathways, genetic context and functional data to identify synthetic lethal vulnerabilities in cancers driven by tumor suppressor gene loss or immune evasion. The platform underpins a pipeline of wholly owned, genetically defined drug candidates.

The lead asset is vopimetostat (TNG462), a next-generation MTA-cooperative PRMT5 inhibitor that selectively kills MTAP-deleted cancer cells (preclinical potency 4 nM, 45x selectivity over normal cells). In June 2026 Tango reported a 92% objective response rate for vopimetostat combined with Revolution Medicines' daraxonrasib in MTAP-deleted/RAS-mutant metastatic pancreatic cancer and announced plans for a Phase 3 trial in first-line MTAP-deleted pancreatic cancer. The second clinical PRMT5 inhibitor, TNG456, is a brain-penetrant molecule (potency 20 nM, 55x selectivity) in Phase 1/2 for MTAP-deleted glioblastoma and non-small cell lung cancer. Earlier-stage assets include TNG908 (PRMT5), the discontinued TNG260 co-repressor disruptor, and TNG961, an oral HBS1L molecular glue degrader for FOCAD-deleted cancers disclosed at AACR 2026.

Tango has no commercialized products and does not sell software or services. Revenue is generated entirely from collaboration and licensing agreements with pharmaceutical partners (Revolution Medicines, Erasca, Gilead), and is episodic and milestone-driven — FY2024 revenue was $62.38 million (a 48.3% YoY increase) and Q3 2025 collaboration revenue alone was $53.8 million, while Q4 2025 and Q1 2026 reported zero collaboration revenue. The company funds its operations primarily through equity capital markets, having raised approximately $925M between October 2025 and June 2026 to extend its cash runway into 2028 and to fund late-stage clinical development of vopimetostat.

Short descriptiontext

Tango Therapeutics is a clinical-stage biotechnology company that uses a proprietary CRISPR-based functional genomics platform to discover synthetic lethal precision oncology drug candidates, with its lead PRMT5 inhibitor vopimetostat advancing toward Phase 3 in MTAP-deleted pancreatic cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
precision oncology therapeutics, synthetic lethality drugs, PRMT5 inhibitors, CRISPR drug discovery, MTAP-deleted cancer therapies
Industry2 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration and licensing revenue
TypeLicensing Royalties
Description

Tango Therapeutics generates revenue from collaboration agreements with pharmaceutical partners. Q3 2025 revenue of $53.8M was reported (matching FactSet estimate), while Q4 2025 and Q1 2026 reported zero collaboration revenue, indicating episodic, milestone-driven collaboration receipts rather than recurring revenue. Historical revenue was $5.4M in Q1 2025 and $62.38M for full year 2025 (a 48.3% YoY increase).

marketscreener.com
2Equity financing (capital markets)
TypeTransaction Fee
Description

Clinical-stage biotech funded primarily through equity financings including: $80M private placement (Aug 2023, Nextech, Bain Capital Life Sciences), $210M underwritten equity offering + $15M PIPE (Oct 2025, total $225M), $100M ATM facility (Feb 2026, Leerink Partners), $500M public offering launch (June 8, 2026), upsized to $600M (June 10, 2026), and a Boxer Capital $9.5M secondary-market purchase (Feb 2026).

stocktitan.net
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Vopimetostat (TNG462)
Description

Next-generation MTA-cooperative PRMT5 inhibitor in clinical development for MTAP-deleted cancers including pancreatic and lung cancers.

tangotx.com
+4 more records
Core offering1 text field

Tango Therapeutics is a clinical-stage biotechnology company that discovers and develops precision oncology drug candidates using a proprietary CRISPR-based functional genomics platform focused on synthetic lethality. Its lead asset is Vopimetostat (TNG462), a next-generation MTA-cooperative PRMT5 inhibitor being advanced in Phase 1/2 and toward Phase 3 trials for MTAP-deleted pancreatic and lung cancers, supplemented by TNG456 (brain-penetrant PRMT5 inhibitor), TNG908, and earlier-stage programs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Tango Therapeutics is a clinical-stage biotechnology company that operates a platform-plus-candidates model. The platform — a proprietary CRISPR-based functional genomics target discovery engine — identifies novel synthetic lethal vulnerabilities in cancer cells with specific tumor suppressor gene loss, and feeds a pipeline of wholly-owned precision oncology drug candidates. The lead asset is Vopimetostat (TNG462), an MTA-cooperative PRMT5 inhibitor in Phase 1/2 and heading toward Phase 3 in MTAP-deleted pancreatic cancer; the second clinical PRMT5 inhibitor, TNG456, targets MTAP-deleted glioblastoma and NSCLC with blood-brain barrier penetrance. Earlier-stage and discovery programs include TNG908 (PRMT5 inhibitor), TNG260 (discontinued co-repressor disruptor), and TNG961 (an HBS1L molecular glue degrader for FOCAD-deleted cancers presented at AACR 2026). The portfolio is augmented by clinical collaborations with Revolution Medicines and Erasca, combining vopimetostat with their RAS(ON) inhibitors in MTAP-deleted/RAS-mutant solid tumors.

Product and service5 records
1Vopimetostat (TNG462)
CategoryLead drug candidate (PRMT5 inhibitor)
Description

Next-generation MTA-cooperative PRMT5 inhibitor designed to selectively kill MTAP-deleted cancer cells while sparing normal cells. Demonstrated 45x selectivity and 4 nM potency in MTAP-deleted cells preclinically; advancing into Phase 3 for first-line MTAP-deleted pancreatic cancer based on a 92% ORR in combination with daraxonrasib.

2TNG456
CategoryDrug candidate (PRMT5 inhibitor)
Description

Next-generation blood-brain barrier penetrant MTA-cooperative PRMT5 inhibitor with 55x selectivity and 20 nM potency in MTAP-deleted cells; being developed for MTAP-deleted glioblastoma and non-small cell lung cancer.

3TNG908
CategoryDrug candidate (PRMT5 inhibitor)
Description

Investigational PRMT5 inhibitor evaluated in a clinical trial (NCT05275478) for safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in patients with MTAP-deleted cancers.

4TNG260
CategoryDiscontinued drug candidate (co-repressor complex disruptor)
Description

Investigational co-repressor complex disruptor previously evaluated in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors with STK11 loss-of-function mutation and KRAS wild type (NCT05887492). Program discontinued.

5TNG961
CategoryDiscovery-stage drug candidate (HBS1L molecular glue degrader)
Description

Selective, oral HBS1L molecular glue degrader disclosed at AACR April 2026 for the treatment of FOCAD-deleted cancers; currently in discovery/research stage.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology company targeting chromatin biology, including synthetic-lethal and gene-regulatory mechanisms. Comparable platform-plus-candidates model and clinical stage to Tango.

TypeDirect peer
Description

Clinical-stage precision oncology company developing RAS-pathway inhibitors (including pan-RAS molecular glue ERAS-0015). Active clinical-trial collaborator with Tango on vopimetostat combinations for MTAP-del/RAS-mutant tumors.

TypeDirect peer
Description

Clinical-stage precision oncology company using synthetic lethality to develop targeted cancer therapies. Most directly comparable to Tango given shared synthetic-lethal discovery approach and pipeline of genetically defined oncology candidates.

4Theseus Pharmaceuticals
TypeEmerging player
Description

Clinical-stage oncology company developing targeted kinase inhibitors, including programs addressing resistance mutations. Smaller-scale precision oncology peer with overlapping therapeutic-area focus.

TypeDirect peer
Description

Clinical-stage oncology company developing RAS(ON) inhibitors including daraxonrasib. Direct strategic partner and combination-trial collaborator with Tango on vopimetostat, while also competing in the broader MTAP-del/RAS-mutant pancreatic cancer space.

TypeEmerging player
Description

Clinical-stage precision oncology company focused on genetically defined cancers and rare tumor types. Comparable clinical-stage peer in targeted oncology with overlapping indication strategy.

TypeDirect peer
Description

Clinical-stage precision oncology company using a proprietary discovery platform to develop targeted therapies against oncogenic mutations. Comparable in scale, stage, and genetically defined precision oncology approach.

TypeEmerging player
Description

Clinical-stage biotech developing targeted protein degraders (PROTAC and molecular glue degraders). Comparable as Tango also disclosed a molecular glue degrader (TNG961, HBS1L), placing both in the targeted protein degradation and synthetic-lethal oncology space.

9Nuvalent
TypeDirect peer
Description

Clinical-stage precision oncology company developing selectively designed kinase inhibitors for genetically defined cancers, including lung cancer programs. Comparable clinical-stage biotech in the precision-oncology and targeted-therapy category.

TypeBroad incumbent
Description

Established commercial-stage precision oncology company developing kinase inhibitors for genomically defined cancers. Broader peer operating at larger scale and with commercial revenue in the same genetically targeted oncology category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tango Therapeutics

Precision Oncology Therapeuticstangotx.com

Tango Therapeutics is a clinical-stage biotechnology company that uses a proprietary CRISPR-based functional genomics platform to discover synthetic lethal precision oncology drug candidates, with its lead PRMT5 inhibitor vopimetostat advancing toward Phase 3 in MTAP-deleted pancreatic cancer.

What Tango Therapeutics does

Tango Therapeutics is a clinical-stage biotechnology company developing next-generation precision oncology medicines based on the principle of synthetic lethality. Founded in 2017 and headquartered in Boston, Massachusetts, the company is publicly listed on NASDAQ under ticker TNGX and employs between 101 and 250 people. Tango's core technology is a proprietary CRISPR-based functional genomics target discovery platform that integrates targets, pathways, genetic context and functional data to identify synthetic lethal vulnerabilities in cancers driven by tumor suppressor gene loss or immune evasion. The platform underpins a pipeline of wholly owned, genetically defined drug candidates.

The lead asset is vopimetostat (TNG462), a next-generation MTA-cooperative PRMT5 inhibitor that selectively kills MTAP-deleted cancer cells (preclinical potency 4 nM, 45x selectivity over normal cells). In June 2026 Tango reported a 92% objective response rate for vopimetostat combined with Revolution Medicines' daraxonrasib in MTAP-deleted/RAS-mutant metastatic pancreatic cancer and announced plans for a Phase 3 trial in first-line MTAP-deleted pancreatic cancer. The second clinical PRMT5 inhibitor, TNG456, is a brain-penetrant molecule (potency 20 nM, 55x selectivity) in Phase 1/2 for MTAP-deleted glioblastoma and non-small cell lung cancer. Earlier-stage assets include TNG908 (PRMT5), the discontinued TNG260 co-repressor disruptor, and TNG961, an oral HBS1L molecular glue degrader for FOCAD-deleted cancers disclosed at AACR 2026.

Tango has no commercialized products and does not sell software or services. Revenue is generated entirely from collaboration and licensing agreements with pharmaceutical partners (Revolution Medicines, Erasca, Gilead), and is episodic and milestone-driven — FY2024 revenue was $62.38 million (a 48.3% YoY increase) and Q3 2025 collaboration revenue alone was $53.8 million, while Q4 2025 and Q1 2026 reported zero collaboration revenue. The company funds its operations primarily through equity capital markets, having raised approximately $925M between October 2025 and June 2026 to extend its cash runway into 2028 and to fund late-stage clinical development of vopimetostat.

Tango Therapeutics firmographics

Firmographics
Name
Tango Therapeutics
Legal name
Tango Therapeutics, Inc.
Website
https://tangotx.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Tango Therapeutics is a clinical-stage biotechnology company that uses a proprietary CRISPR-based functional genomics platform to discover synthetic lethal precision oncology drug candidates, with its lead PRMT5 inhibitor vopimetostat advancing toward Phase 3 in MTAP-deleted pancreatic cancer.
Ownership category
akta.pro rank

Tango Therapeutics industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision oncology therapeutics
  • Synthetic lethality drugs
  • PRMT5 inhibitors
  • CRISPR drug discovery
  • MTAP-deleted cancer therapies

Where Tango Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Tango Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Collaboration and licensing revenue: Tango Therapeutics generates revenue from collaboration agreements with pharmaceutical partners. Q3 2025 revenue of $53.8M was reported (matching FactSet estimate), while Q4 2025 and Q1 2026 reported zero collaboration revenue, indicating episodic, milestone-driven collaboration receipts rather than recurring revenue. Historical revenue was $5.4M in Q1 2025 and $62.38M for full year 2025 (a 48.3% YoY increase).
  2. Equity financing (capital markets): Clinical-stage biotech funded primarily through equity financings including: $80M private placement (Aug 2023, Nextech, Bain Capital Life Sciences), $210M underwritten equity offering + $15M PIPE (Oct 2025, total $225M), $100M ATM facility (Feb 2026, Leerink Partners), $500M public offering launch (June 8, 2026), upsized to $600M (June 10, 2026), and a Boxer Capital $9.5M secondary-market purchase (Feb 2026).

Go-to-market motion3 records

Tango Therapeutics product offering

Product offering

Core offering

Tango Therapeutics is a clinical-stage biotechnology company that discovers and develops precision oncology drug candidates using a proprietary CRISPR-based functional genomics platform focused on synthetic lethality. Its lead asset is Vopimetostat (TNG462), a next-generation MTA-cooperative PRMT5 inhibitor being advanced in Phase 1/2 and toward Phase 3 trials for MTAP-deleted pancreatic and lung cancers, supplemented by TNG456 (brain-penetrant PRMT5 inhibitor), TNG908, and earlier-stage programs.

Product overview

Tango Therapeutics is a clinical-stage biotechnology company that operates a platform-plus-candidates model. The platform — a proprietary CRISPR-based functional genomics target discovery engine — identifies novel synthetic lethal vulnerabilities in cancer cells with specific tumor suppressor gene loss, and feeds a pipeline of wholly-owned precision oncology drug candidates. The lead asset is Vopimetostat (TNG462), an MTA-cooperative PRMT5 inhibitor in Phase 1/2 and heading toward Phase 3 in MTAP-deleted pancreatic cancer; the second clinical PRMT5 inhibitor, TNG456, targets MTAP-deleted glioblastoma and NSCLC with blood-brain barrier penetrance. Earlier-stage and discovery programs include TNG908 (PRMT5 inhibitor), TNG260 (discontinued co-repressor disruptor), and TNG961 (an HBS1L molecular glue degrader for FOCAD-deleted cancers presented at AACR 2026). The portfolio is augmented by clinical collaborations with Revolution Medicines and Erasca, combining vopimetostat with their RAS(ON) inhibitors in MTAP-deleted/RAS-mutant solid tumors.

Differentiator

Problem solved

Functional benefit

Brands

  • Vopimetostat (TNG462): Next-generation MTA-cooperative PRMT5 inhibitor in clinical development for MTAP-deleted cancers including pancreatic and lung cancers.
  • TNG456
  • TNG908
  • TNG260
  • TNG961

Products and services

  • Vopimetostat (TNG462) Next-generation MTA-cooperative PRMT5 inhibitor designed to selectively kill MTAP-deleted cancer cells while sparing normal cells. Demonstrated 45x selectivity and 4 nM potency in MTAP-deleted cells preclinically; advancing into Phase 3 for first-line MTAP-deleted pancreatic cancer based on a 92% ORR in combination with daraxonrasib.
  • TNG456 Next-generation blood-brain barrier penetrant MTA-cooperative PRMT5 inhibitor with 55x selectivity and 20 nM potency in MTAP-deleted cells; being developed for MTAP-deleted glioblastoma and non-small cell lung cancer.
  • TNG908 Investigational PRMT5 inhibitor evaluated in a clinical trial (NCT05275478) for safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in patients with MTAP-deleted cancers.
  • TNG260 Investigational co-repressor complex disruptor previously evaluated in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors with STK11 loss-of-function mutation and KRAS wild type (NCT05887492). Program discontinued.
  • TNG961 Selective, oral HBS1L molecular glue degrader disclosed at AACR April 2026 for the treatment of FOCAD-deleted cancers; currently in discovery/research stage.

Companies that use Tango Therapeutics

Customer profile

Ideal customer profiles2 records

Tango Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Tango Therapeutics partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

Tango Therapeutics competitors and assessment

Company assessment

Direct peers

  • Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin biology, including synthetic-lethal and gene-regulatory mechanisms. Comparable platform-plus-candidates model and clinical stage to Tango.
  • Erasca: Clinical-stage precision oncology company developing RAS-pathway inhibitors (including pan-RAS molecular glue ERAS-0015). Active clinical-trial collaborator with Tango on vopimetostat combinations for MTAP-del/RAS-mutant tumors.
  • Repare Therapeutics: Clinical-stage precision oncology company using synthetic lethality to develop targeted cancer therapies. Most directly comparable to Tango given shared synthetic-lethal discovery approach and pipeline of genetically defined oncology candidates.
  • Revolution Medicines: Clinical-stage oncology company developing RAS(ON) inhibitors including daraxonrasib. Direct strategic partner and combination-trial collaborator with Tango on vopimetostat, while also competing in the broader MTAP-del/RAS-mutant pancreatic cancer space.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company using a proprietary discovery platform to develop targeted therapies against oncogenic mutations. Comparable in scale, stage, and genetically defined precision oncology approach.
  • Nuvalent: Clinical-stage precision oncology company developing selectively designed kinase inhibitors for genetically defined cancers, including lung cancer programs. Comparable clinical-stage biotech in the precision-oncology and targeted-therapy category.

Emerging players

  • Theseus Pharmaceuticals: Clinical-stage oncology company developing targeted kinase inhibitors, including programs addressing resistance mutations. Smaller-scale precision oncology peer with overlapping therapeutic-area focus.
  • SpringWorks Therapeutics: Clinical-stage precision oncology company focused on genetically defined cancers and rare tumor types. Comparable clinical-stage peer in targeted oncology with overlapping indication strategy.
  • Arvinas: Clinical-stage biotech developing targeted protein degraders (PROTAC and molecular glue degraders). Comparable as Tango also disclosed a molecular glue degrader (TNG961, HBS1L), placing both in the targeted protein degradation and synthetic-lethal oncology space.

Broad incumbents

  • Blueprint Medicines: Established commercial-stage precision oncology company developing kinase inhibitors for genomically defined cancers. Broader peer operating at larger scale and with commercial revenue in the same genetically targeted oncology category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Tango Therapeutics social profiles

Digital presence

Tango Therapeutics compliance and trust

Trust signal

Compliance3 records

Tango Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tango Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Tango Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tango Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tango Therapeutics

What does Tango Therapeutics do?

Tango Therapeutics is a clinical-stage biotechnology company that discovers and develops precision oncology drug candidates using a proprietary CRISPR-based functional genomics platform focused on synthetic lethality. Its lead asset is Vopimetostat (TNG462), a next-generation MTA-cooperative PRMT5 inhibitor being advanced in Phase 1/2 and toward Phase 3 trials for MTAP-deleted pancreatic and lung cancers, supplemented by TNG456 (brain-penetrant PRMT5 inhibitor), TNG908, and earlier-stage programs.

Is Tango Therapeutics a public or private company?

Tango Therapeutics is a public company. It is classified as public and is currently operating.

When was Tango Therapeutics founded?

Tango Therapeutics was founded in 2017. It employs 101 to 250 people.

Where is Tango Therapeutics based?

Tango Therapeutics is headquartered in Boston, United States, in the North America region.

How does Tango Therapeutics make money?

Two revenue lines are on record. Collaboration and licensing revenue is the primary driver. The others are equity financing (capital markets).

Who are Tango Therapeutics's main competitors?

Direct peers on record are Foghorn Therapeutics, Erasca, Repare Therapeutics, Revolution Medicines, Black Diamond Therapeutics and Nuvalent. Emerging players are Theseus Pharmaceuticals, SpringWorks Therapeutics and Arvinas. Blueprint Medicines is listed as a broad incumbent.

Does Tango Therapeutics have an API?

No public API is recorded for Tango Therapeutics.

What industry is Tango Therapeutics in?

Tango Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldTango Therapeutics, Inc. $TNGX Stock Acquired by Fisher Asset Management LLCFisher Asset Management increased its stake in Tango Therapeutics by 84.8% in Q3, holding 1,068,505 shares. Analysts rate the stock a Moderate Buy with an average price target of $45.54, while insiders sold 52,231 shares in the last three months.Simply Wall StTango Therapeutics (TNGX) Climbed, So What Is Driving Attention Now?Tango Therapeutics launched a Phase 1/2 trial combining vopimetostat with ERAS-0015 for MTAP-deleted pancreatic and lung cancers, while its stock rose 18.60% over seven days and 185.55% year-to-date. Analysts set a fair value of $47.09 versus a $25.50 close, citing the vopimetostat franchise's potential but also trial-related volatility.American Banking and Market NewsTango Therapeutics (NASDAQ:TNGX) Stock Price Target Cut by WedbushWedbush cut its price target on Tango Therapeutics from $45 to $40, keeping an outperform rating. The stock opened at $25.73, with an average analyst target of $45.54. The company reported a loss of $0.39 per share for the quarter, missing estimates.American Banking and Market NewsHC Wainwright Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock PriceHC Wainwright lowered its price target on Tango Therapeutics from $68 to $67, keeping a buy rating. The stock opened at $25.73, with a consensus rating of Moderate Buy and an average target of $45.54. Insiders sold 47,231 shares over the past 90 days.Defense WorldTango Therapeutics (NASDAQ:TNGX) Given New $67.00 Price Target at HC WainwrightHC Wainwright cut its price target on Tango Therapeutics from $68 to $67, keeping a Buy rating. The company reported a Q3 loss of $0.39 per share, missing the $0.35 consensus estimate. Analysts have a consensus rating of Moderate Buy with a target of $45.54.American Banking and Market NewsJPMorgan Chase & Co. Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock PriceJPMorgan raised its price target on Tango Therapeutics to $47 from $46, maintaining an Overweight rating. The company reported a Q3 loss of $0.39 per share, missing the consensus estimate of $0.35. Tango expects to start a registrational Phase 3 trial in front-line MTAP-deleted pancreatic cancer in the first half of 2027.Investing.comTango Therapeutics at guggenheim healthcare conference: late-stage pushTango Therapeutics presented its late-stage development strategy at the Guggenheim Healthcare conference, focusing on vopimetostat plus daraxonrasib for pancreatic cancer. The company reported an 82% response rate in 22 pancreatic cancer patients and plans a Phase III frontline study starting in H1 2025. It is still negotiating a supply agreement with Revolution Medicines for daraxonrasib.American Banking and Market NewsCandriam S.C.A. Sells 1,152,632 Shares of Tango Therapeutics, Inc. $TNGXCandriam S.C.A. sold 1,152,632 shares of Tango Therapeutics in Q3, reducing its stake by 70.7% to 477,921 shares. Other funds also adjusted positions, and analysts rate the stock a Moderate Buy with a $44.62 target.MarketScreenerTango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Tango Therapeutics reported a Q3 net loss of $68.39 million and a nine-month net loss of $169.25 million, both worse than the prior year. Basic loss per share was $0.39 in Q3 and $1.08 for nine months, compared to prior-year earnings per share.YahooTango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business HighlightsTango Therapeutics reported Q3 2026 financial results, including a $68.4 million net loss and $977.5 million in cash. The company presented Phase 1/2 data showing an 82% objective response rate for vopimetostat plus daraxonrasib in pancreatic cancer, and plans to initiate a Phase 3 study in 2027.